Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review.
Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Rowin EJ, Maron MS, Sherrid MV.
J Am Coll Cardiol. 2022 Feb 1;79(4):372-389. doi: 10.1016/j.jacc.2021.12.002.
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy.
Ho CY, Mealiffe ME, Bach RG, Bhattacharya M, Choudhury L, Edelberg JM, Hegde SM, Jacoby D, Lakdawala NK, Lester SJ, Ma Y, Marian AJ, Nagueh SF, Owens A, Rader F, Saberi S, Sehnert AJ, Sherrid MV, Solomon SD, Wang A, Wever-Pinzon O, Wong TC, Heitner SB.
J Am Coll Cardiol. 2020 Jun 2;75(21):2649-2660. doi: 10.1016/j.jacc.2020.03.064.
Hypertrophic cardiomyopathy: the future of treatment.
Tuohy CV, Kaul S, Song HK, Nazer B, Heitner SB.
Eur J Heart Fail. 2020 Feb;22(2):228-240. doi: 10.1002/ejhf.1715. Epub 2020 Jan 9.
Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review.
Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Dearani JA, Rowin EJ, Maron MS, Sherrid MV.
J Am Coll Cardiol. 2022 Feb 1;79(4):390-414. doi: 10.1016/j.jacc.2021.11.021.
Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored Until Now.
Maron BJ, Rowin EJ, Maron MS, Braunwald E.
Am J Med. 2017 Feb;130(2):119-123. doi: 10.1016/j.amjmed.2016.09.015. Epub 2016 Oct 14.
Nonobstructive Hypertrophic Cardiomyopathy: Overlooked But Not Forgotten.
Maron BJ, Maron MS.
Mayo Clin Proc. 2016 Mar;91(3):277-8. doi: 10.1016/j.mayocp.2016.01.004.
Nonobstructive Hypertrophic Cardiomyopathy-The High-Hanging Fruit.
Day SM.
JAMA Cardiol. 2019 Mar 1;4(3):235-236. doi: 10.1001/jamacardio.2018.4953.
Long-term outcome of nonobstructive versus obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis.
Pelliccia F, Pasceri V, Limongelli G, Autore C, Basso C, Corrado D, Imazio M, Rapezzi C, Sinagra G, Mercuro G; Working Group on Cardiomyopathies and Pericardial Diseases of the Italian Society of Cardiology.
Int J Cardiol. 2017 Sep 15;243:379-384. doi: 10.1016/j.ijcard.2017.06.071.
Delayed-release rapamycin halts progression of left ventricular hypertrophy in subclinical feline hypertrophic cardiomyopathy: results of the RAPACAT trial.
Kaplan JL, Rivas VN, Walker AL, Grubb L, Farrell A, Fitzgerald S, Kennedy S, Jauregui CE, Crofton AE, McLaughlin C, Van Zile R, DeFrancesco TC, Meurs KM, Stern JA.
J Am Vet Med Assoc. 2023 Jul 26;261(11):1628-1637. doi: 10.2460/javma.23.04.0187. Print 2023 Nov 1.
Identifying Obstructive Hypertrophic Cardiomyopathy from Nonobstructive Hypertrophic Cardiomyopathy: Development and Validation of a Model Based on Electrocardiogram Features.
Guo L, Ma Z, Yang W, Zhang F, Shao H, Liu L, Gao C, Tao L.
Glob Heart. 2023 Aug 4;18(1):40. doi: 10.5334/gh.1250. eCollection 2023.
